Kay L Saving
Overview
Explore the profile of Kay L Saving including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hildenbrand A, Mara C, Murphy B, Hood A, Johnson Y, Shook L, et al.
Pediatr Blood Cancer
. 2025 Mar;
:e31639.
PMID: 40051208
Background: Guidelines recommend that hydroxyurea be offered to children with sickle cell disease (SCD) as early as 9 months of age using shared decision-making. To help clinicians implement shared decision-making...
2.
Mendez G, Nocek J, Brambilla D, Jacobs S, Cole O, Kanter J, et al.
BMC Health Serv Res
. 2024 Mar;
24(1):291.
PMID: 38448911
Background: Adults with sickle cell disease (SCD) suffer early mortality and high morbidity. Many are not affiliated with SCD centers, defined as no ambulatory visit with a SCD specialist in...
3.
Hood A, Strong H, Nwankwo C, Johnson Y, Peugh J, Mara C, et al.
JMIR Res Protoc
. 2021 May;
10(5):e27650.
PMID: 34018965
Background: Sickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization. Until...
4.
Meier E, Creary S, Heeney M, Dong M, Appiah-Kubi A, Nelson S, et al.
Trials
. 2020 Nov;
21(1):983.
PMID: 33246482
Background: Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide. Hydroxyurea is the primary disease-modifying therapy for...
5.
Kimrey S, Saving K
Pediatr Ann
. 2020 Jan;
49(1):e43-e49.
PMID: 31930422
Sickle cell disease is an autosomal recessive disorder with significant global impact. This disorder causes the production of a dysfunctional hemoglobin, which leads to sickling of erythrocytes and ultimately hemolysis,...
6.
Crosby L, Walton A, Shook L, Ware R, Treadwell M, Saving K, et al.
J Pediatr Hematol Oncol
. 2018 Jul;
41(1):56-63.
PMID: 30044352
National evidence-based guidelines recommend offering hydroxyurea to patients with sickle cell anemia 9 months of age and older using shared decision making, but offer no strategies to aid implementation. We...
7.
Hankins J, Estepp J, Hodges J, Villavicencio M, Robison L, Weiss M, et al.
Pediatr Blood Cancer
. 2018 May;
65(9):e27228.
PMID: 29797644
Background: Previous natural history studies have advanced the understanding of sickle cell disease (SCD), but generally have not included sufficient lifespan data or investigation of the role of genetics in...
8.
Shook L, Farrell C, Kalinyak K, Nelson S, Hardesty B, Rampersad A, et al.
Med Educ Online
. 2016 Nov;
21():33616.
PMID: 27887664
Background: Approximately 100,000 persons with sickle cell disease (SCD) live in the United States, including 15,000 in the Midwest. Unfortunately, many patients experience poor health outcomes due to limited access...
9.
Dasari V, Veeravalli K, Saving K, Gujrati M, Fassett D, Klopfenstein J, et al.
Neurobiol Dis
. 2008 Oct;
32(3):486-98.
PMID: 18930139
The neurotransmitter glutamate mediates excitatory synaptic transmission in the brain and spinal cord. In pathological conditions massive glutamate release reaches near millimolar concentrations in the extracellular space and contributes to...
10.
Dasari V, Spomar D, Gondi C, Sloffer C, Saving K, Gujrati M, et al.
J Neurotrauma
. 2007 Mar;
24(2):391-410.
PMID: 17376002
Human umbilical cord blood stem cells (hUCB) hold great promise for therapeutic repair after spinal cord injury (SCI). Here, we present our preliminary investigations on axonal remyelination of injured spinal...